Pfizer announces €300m investment in Irish manufacturing sites
pharmafile | November 2, 2020 | News story | Sales and Marketing |
Pfizer is set to invest €300 million in its three Irish manufacturing sites in Ringaskiddy, Dublin and Kildare.
The investment will provide additional manufacturing and laboratory capacity, creating 300 roles over the next two to three years. The roles being created comprise a wide array of highly skilled positions such as engineers, scientists, technicians, scientists and chemists.
Part of this investment will allow the construction of a site at Ringaskiddy to manufacture pharmaceutical compounds for the company’s clinical trials across the globe. It will also mark the shift from manufacturing to support the earlier phases of medicine development.
Ringaskiddy was Pfizer’s first investment in Ireland back in 1969 and originally employed 16 people. The company says, so far, it has invested $8 billion into its operations in the country.
“This is a very important development. As it expands Pfizer’s role in Ireland from the manufacture of already approved medicines into the support of an earlier phase of new medicine development,” remarked Paul Duffy, Vice-President of Global Supply for Pfizer. “It is also particularly exciting that our Ringaskiddy site has been chosen as the location to manufacture investigational compounds for our clinical trials globally and we look forward to seeing that new facility become operational.”
The company released a statement saying that this new investment will “expand manufacturing and laboratory capacity and add new technologies to ensure Pfizer is ready to support the next wave of medical innovations.”
The Irish Government has responded to the new investment. Taoiseach Micheal Martin said it was a further vote of confidence in Ireland, adding: “Pfizer’s footprint in Ireland was first established in Ringaskiddy in Cork in 1969, marking the beginning of a new era of pharmaceutical investment in Ireland.
“Pfizer has made a significant contribution to the Irish economy and this latest investment is a testament to the quality and experience of the workforce here.”
Conor Kavanagh
